Metabolic Disease News and Research

RSS
Research offers new hope for rare metabolic disorder

Research offers new hope for rare metabolic disorder

New type of fat-producing cells may speed up treatments for muscular dystrophy and fibrosis

New type of fat-producing cells may speed up treatments for muscular dystrophy and fibrosis

CRF awards $1.75 million in 11 new grants to researchers to find a cure for cystinosis

CRF awards $1.75 million in 11 new grants to researchers to find a cure for cystinosis

Alnylam Pharmaceuticals receives payment from Roche to initiate pre-IND studies for RNAi therapeutics

Alnylam Pharmaceuticals receives payment from Roche to initiate pre-IND studies for RNAi therapeutics

VIA Pharmaceuticals receives NASDAQ delisting notice

VIA Pharmaceuticals receives NASDAQ delisting notice

Tranzyme Pharma and Bristol-Myers Squibb sign collaboration agreement

Tranzyme Pharma and Bristol-Myers Squibb sign collaboration agreement

Last patient visit complete in VIA Pharmaceuticals' Phase 2 FDG-PET trial

Last patient visit complete in VIA Pharmaceuticals' Phase 2 FDG-PET trial

Jubilant Organosys, UAB and Southern Research Institute announce joint venture to accelerate global drug development

Jubilant Organosys, UAB and Southern Research Institute announce joint venture to accelerate global drug development

Additional data from Aegerion Pharmaceuticals' ongoing lomitapide Phase III trial

Additional data from Aegerion Pharmaceuticals' ongoing lomitapide Phase III trial

Phase I clinical study for ETC-1002 commenced

Phase I clinical study for ETC-1002 commenced

Data on Puredel's Ossulin to be presented at the San Francisco Diabetes Technology Meeting

Data on Puredel's Ossulin to be presented at the San Francisco Diabetes Technology Meeting

Alnylam Pharmaceuticals and Roche team up to develop specific RNAi therapeutic products

Alnylam Pharmaceuticals and Roche team up to develop specific RNAi therapeutic products

Ligand Pharmaceuticals amends license agreement with Exelixis

Ligand Pharmaceuticals amends license agreement with Exelixis

Amylin and Takeda to develop and commercialize pharmaceutical products for obesity

Amylin and Takeda to develop and commercialize pharmaceutical products for obesity

VIA Pharmaceuticals to discuss its cardio-metabolic product portfolio at the Target 2009 conference

VIA Pharmaceuticals to discuss its cardio-metabolic product portfolio at the Target 2009 conference

Monash University physiologist honored with Life Scientist of the Year award

Monash University physiologist honored with Life Scientist of the Year award

Curriculum to increase science literacy and generate enthusiasm for life sciences among high school students

Curriculum to increase science literacy and generate enthusiasm for life sciences among high school students

Amarin selects Medpace as CRO for its Phase 3 AMR101 MARINE clinical study

Amarin selects Medpace as CRO for its Phase 3 AMR101 MARINE clinical study

Metabolic master switch sets the biological clock in body tissues

Metabolic master switch sets the biological clock in body tissues

VIA Pharmaceuticals receives determination letter from NASDAQ Stock Market

VIA Pharmaceuticals receives determination letter from NASDAQ Stock Market